Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.

Antimicrobial agents and chemotherapy - 1 Jun 2011

Gupta Soumi, Vingerhoets Johan, Fransen Signe, Tambuyzer Lotke, Azijn Hilde, Frantzell Arne, Paredes Roger, Coakley Eoin, Nijs Steven, Clotet Bonaventura, Petropoulos Christos J, Schapiro Jonathan, Huang Wei, Picchio Gaston

Abstract excerpt

Connection domain mutations (CDMs) in HIV-1 reverse transcriptase (RT) alter susceptibility to some nucleoside/nonnucleoside RT inhibitors (NRTIs/NNRTIs). Their effects on susceptibility and virologic responses to etravirine were analyzed. Seventeen CDMs were evaluated: L283I, E312Q, G333D, G333E, G335C, G335D, N348I, A360I, A360T, A360V, V365I, T369I, A371V, A376S, I393L, E399D, and E399G. CDM prevalence and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Reverse Transcriptase

Share to Mutagenesis, Site-Directed

Share to Nitriles

Share to Pyridazines

Share to Pyrimidines

Share to Reverse Transcriptase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 21464253
DOI: 10.1128/AAC.01695-10
PMCID: PMC3101386

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.PMID 21464253Read ↗

Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.Semantic proximity Read ↗

HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy.Semantic proximity Read ↗

Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing.Semantic proximity Read ↗

Connection domain mutations in treatment-experienced patients in the OPTIMA trial.Semantic proximity Read ↗

Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity.Semantic proximity Read ↗

Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase InhibitorsSemantic proximity Read ↗

HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitorsSemantic proximity Read ↗

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.Semantic proximity Read ↗

Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility.Semantic proximity Read ↗

A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.Semantic proximity Read ↗

Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance.Semantic proximity Read ↗

Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.